Sialometrical and sialochemical analysis of patients with chronic graft-versus-host disease--a prolonged study.
Patients with graft-versus-host disease (cGVHD) suffer from oral dryness and increased levels of oral infections and mucosal pathologies. The purpose of the current study was dual: 1) to investigate the salivary functional (sialometry) and compositional (sialochemistry) alterations induced by the disease during a 12-month period following the onset of the disease; and 2) to evaluate the effect of Salagen 30 mg/d on the salivary biochemical and immunological composition in cGVHD patients. Significant higher concentrations of salivary sodium (Na), magnesium (Mg), total protein (TP), albumin (Alb), epidermal growth factor (EGF), and total IgG accompanied by a concomitant increase in total IgA that did not reach significant value was observed in cGVHD patients in comparison with controls at both resting and stimulated conditions (p < 0.05) while salivary levels of potassium (K), calcium (Ca), and phosphate (P) were not altered. Two weeks of oral Salagen 30 mg/d resulted in normalization of the salivary biochemical and immunological compositional alterations in the cGVHD patients. Oral pilocarpine was able to reduce and normalize the elevated levels of Na, Mg, TP, Alb, EGF, IgG, and IgA salivary concentrations at both resting and stimulated conditions. The ability of oral pilocarpine to normalize and reverse salivary biochemical and immunological alterations induced by cGVHD is parallel to its stimulatory effect on salivary flow rates, as we previously showed. As the biochemical and immunological composition of the saliva results in its antimicrobial protective characteristics, the ability of oral pilocarpine (Salagen) to abrogate cGVHD salivary gland abnormalities may be of clinical importance.
Nagler
R M
RM
Sheba Medical Center, Tel Hashamer, Israel. nagler@tx.technion.ac.il
Nagler
A
A
D000293:Adolescent; D000328:Adult; D000418:Albumins / Q000032:analysis; D002412:Cations / Q000032:analysis*; D002908:Chronic Disease; D004815:Epidermal Growth Factor / Q000032:analysis; D005260:Female; D005500:Follow-Up Studies; D006086:Graft vs Host Disease / Q000150:complications* / Q000378:metabolism; D019337:Hematologic Neoplasms / Q000628:therapy; D006801:Humans; D007071:Immunoglobulin A, Secretory / Q000032:analysis; D007074:Immunoglobulin G / Q000032:analysis; D008297:Male; D008875:Middle Aged; D036102:Peripheral Blood Stem Cell Transplantation; D010862:Pilocarpine / Q000627:therapeutic use*; D012212:Rheology; D012463:Saliva / Q000737:chemistry*; D012471:Salivary Proteins and Peptides / Q000032:analysis*; D012472:Salivation; D014987:Xerostomia / Q000188:drug therapy / Q000209:etiology* / Q000503:physiopathology
D000418:Albumins; D002412:Cations; D007071:Immunoglobulin A, Secretory; D007074:Immunoglobulin G; D012471:Salivary Proteins and Peptides; D010862:Pilocarpine; D004815:Epidermal Growth Factor